The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML).
J. G. Jurcic
Research Funding - Actinium Pharmaceuticals
T. L. Rosenblat
No relevant relationships to disclose
M. R. McDevitt
Consultant or Advisory Role - Actinium Pharmaceuticals
Research Funding - Actinium Pharmaceuticals
N. Pandit-Taskar
No relevant relationships to disclose
J. A. Carrasquillo
No relevant relationships to disclose
S. M. Chanel
No relevant relationships to disclose
C. Ryan
No relevant relationships to disclose
M. G. Frattini
No relevant relationships to disclose
D. Cicic
Employment or Leadership Position - Actinium Pharmaceuticals
S. M. Larson
No relevant relationships to disclose
D. A. Scheinberg
Consultant or Advisory Role - Clinical Advisory Board (U)
Research Funding - Actinium Pharmaceuticals